© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
